Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021
 
NCT04452318
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID 19 outpatientssome concern
156/158 conclusif
  • demonstrated 44 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
Cov-2067 Weinreich (1200mg) Cohort 1, 2020
 
NCT04425629
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID 19 outpatientssome concern
838/840 conclusif
  • demonstrated 71 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
press release December 2021 : Currently authorized REGEN-COV® (casirivimab and imdevimab) antibodies have diminished potency versus Omicron

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).